Haemophilia

Article	Citations
WFH Guidelines for the Management of Hemophilia, 3rd edition	938
Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A	63
The role of telemedicine in the delivery of health care in the COVID‐19 pandemic	53
The World Federation of Hemophilia Annual Global Survey 1999‐2018	49
Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real‐world experience from a large comprehensive treatment centre in the US	39
Emicizumab prophylaxis: Prospective longitudinal real‐world follow‐up and monitoring	37
Synovitis and synovectomy in haemophilia	33
Delivery of AAV‐based gene therapy through haemophilia centres—A need for re‐evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC	31
World Federation of Hemophilia Gene Therapy Registry	30
Biological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophilia	30
Telehealth for delivery of haemophilia comprehensive care during the COVID‐19 pandemic	29
Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‐YOND extension study	28
Genetic causes of haemophilia in women and girls	28
Low immunogenicity of emicizumab in persons with haemophilia A	28
European principles of care for women and girls with inherited bleeding disorders	27
Uncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns	27
Bleeding of unknown cause and unclassified bleeding disorders; diagnosis, pathophysiology and management	27
Physiotherapy interventions for pain management in haemophilia: A systematic review	27
Women and girls with haemophilia: Lessons learned	26
Emicizumab state‐of‐the‐art update	26
Long‐term safety and efficacy of emicizumab for up to 5.8 years and patients’ perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A	25
Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study	25
Outcome measures in Haemophilia: Beyond ABR (Annualized Bleeding Rate)	24
Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real‐world data	24
Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor?	23

Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study	23
Evidence of a disability paradox in patient‐reported outcomes in haemophilia	23
Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays	23
Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel	23
Off‐label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature	22
The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies	22
Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery	21
The Function of extravascular coagulation factor IX in haemostasis	21
Delivering on the promise of gene therapy for haemophilia	20
Long‐term safety and efficacy results from the phase 3b, open‐label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A	20
Haemophilia care in China: Achievements in the past decade	20
Comparison of bypassing agents in patients on emicizumab using global hemostasis assays	19
An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia	19
Clinical phenotype of severe and moderate haemophilia: Who should receive prophylaxis and what is the target trough level?	19
Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and	19
WFH State‐of‐the‐art paper 2020: In vivo lentiviral vector gene therapy for haemophilia	19
Non‐severe haemophilia: Is it benign? – Insights from the PROBE study	18
Laboratory issues in gene therapy and emicizumab	18
von Willebrand disease: Diagnosis and treatment, treatment of women, and genomic approach to diagnosis	17
Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: Illustrative real‐world cases to support shared decision‐making	17
An overview of patients with haemophilia A in China: Epidemiology, disease severity and treatment strategies	17
Registry of patients with congenital bleeding disorders and COVID‐19 in Madrid	17
How we diagnose 2M von Willebrand disease (VWD): Use of a strategic algorithmic approach to distinguish 2M VWD from other VWD types	17
The 2021 von Willebrand disease guidelines: Clarity and controversy	16
Evaluating international Haemophilia Joint Health Score (HJHS) results combined with expert opinion: Options for a shorter HJHS	16
Practical considerations for nonfactor‐replacement therapies in the treatment of haemophilia with inhibitors	16
Women and girls with haemophilia and bleeding tendencies: Outcomes related to menstruation, pregnancy, surgery and other bleeding episodes from a retrospective chart review	16
Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update	16
Invasive procedures in patients with haemophilia: Review of low‐dose protocols and experience with extended half‐life FVIII and FIX concentrates and non‐replacement therapies	16
Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study	16
Women and girls with haemophilia receiving care at specialized haemophilia treatment centres in the United States	16
Hemophilia gene therapy—New country initiatives	15
High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice	15
Health‐related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors—A non‐interventional study	15
Physical activity levels in men with Haemophilia—A single centre UK survey	15
In‐hospital management of persons with haemophilia and COVID‐19: Practical guidance	15
Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experiment	15
Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis	14
An exploration of why men with severe haemophilia might not want gene therapy: The exigency study	14
Management of pregnancy in women with factor VII deficiency: A case series	14
Gene therapy: Practical aspects of implementation	14
Use of ultrasound for assessment of musculoskeletal disease in persons with haemophilia: Results of an International Prophylaxis Study Group global survey	14
Effectiveness of monthly low dose emicizumab prophylaxis without 4‐week loading doses among patients with haemophilia A with and without inhibitors: A case series report	14
Comparative analysis of the pivotal studies of extended half‐life recombinant FVIII products for treatment of haemophilia A	14
Pathological coagulation parameters in as many as 54 patients with autoimmune acquired factor XIII deficiency due to anti–factor XIII autoantibodies	13
Management of COVID‐19‐associated coagulopathy in persons with haemophilia	13
Real‐world cost estimates of initiating emicizumab in US patients with haemophilia A	13
Parental perspectives on gene therapy for children with haemophilia: The Exigency study	13
Efficacy and safety of fibrinogen concentrate for on‐demand treatment of bleeding and surgical prophylaxis in paediatric patients with congenital fibrinogen deficiency	13
Joint replacement for the management of haemophilic arthropathy in patients with inhibitors: A long‐term experience at a single Haemophilia centre	13

Evolution of haemophilia integrated care in the era of gene therapy: Treatment centre’s readiness in United States and EU	13
Managing women‐specific bleeding in inherited bleeding disorders: A multidisciplinary approach	13
Diagnosis of von Willebrand disease: An assessment of the quality of testing in North American laboratories	13
Similar sports participation as the general population in Dutch persons with haemophilia; results from a nationwide study	13
Real‐world analysis of haemophilia patients in China: A single centre's experience	12
The relationship between chronic pain and psychosocial aspects in patients with haemophilic arthropathy. A cross‐sectional study	12
Detection and evaluation of haemophilic arthropathy: Which tools may be considered more reliable	12
Acquired haemophilia A in the postpartum and risk of relapse in subsequent pregnancies: A systematic literature review	12
Gaining more insight into ankle pain in haemophilia: A study exploring pain, structural and functional evaluation of the ankle joint	12
Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study	12
The B‐Natural study—The outcome of immune tolerance induction therapy in patients with severe haemophilia B	12
Occurrence rates of von Willebrand disease among people receiving care in specialized treatment centres in the United States	12
POSTER ABSTRACTS	12
Feasibility and outcomes of low‐dose and low‐frequency prophylaxis with recombinant extended half‐life products (Fc‐rFVIII and Fc‐rFIX) in Ivorian children with hemophilia: Two‐year experience in the	12
Low dose emicizumab prophylaxis in haemophilia a patients: A pilot study from India	12
Lower physical activity and altered body composition in patients with haemophilia compared with healthy controls	12
Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: Results of a UK NEQAS proficiency testing exercise	12
Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique survey	12
The challenge of genetically unresolved haemophilia A patients: Interest of the combination of whole F8 gene sequencing and functional assays	12
Risk of deep venous thrombosis after total knee arthroplasty in patients with haemophilia A	12
Natural anticoagulants: A missing link in mild to moderate bleeding tendencies	11
The critical need for postmarketing surveillance in gene therapy for haemophilia	11
A case of acquired haemophilia A in a 70‐year‐old post COVID‐19 vaccine	11
Assessing the test–retest reliability and smallest detectable change of the Haemophilia Activities List	11
Prophylaxis in children with haemophilia in an evolving treatment landscape	11
Clinical management of woman with bleeding disorders: A survey among European haemophilia treatment centres	11
Befovacimab, an anti‐tissue factor pathway inhibitor antibody: Early termination of the multiple‐dose, dose‐escalating Phase 2 study due to thrombosis	11
Management of comorbidities in haemophilia	11
Health issues in women and girls affected by haemophilia with a focus on nomenclature, heavy menstrual bleeding, and musculoskeletal issues	11
All‐cause mortality and causes of death in persons with haemophilia: A systematic review and meta‐analysis	11
Gynaecological management of women with inherited bleeding disorders. A UK Haemophilia Centres Doctors' Organisation Guideline	11
Cost‐effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti‐FVIII inhibitors in France	11
The rising incidence of acquired haemophilia A in Germany	11
Clinical assessment and point of care ultrasonography: How to diagnose haemophilic synovitis	11
3D gait analysis, haemophilia joint health score, leg muscle laterality and biomarkers of joint damage: A cross‐sectional comparative assessment of haemophilic arthropathy	11
Real‐world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors	11
Impact of haemophilia on patients with mild‐to‐moderate disease: Results from the P‐FiQ and B‐HERO‐S studies	11
Adoption of emicizumab (Hemlibra®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey	11
Osteoporosis management and falls prevention in patients with haemophilia: Review of haemophilia guidelines	10
Validation of a new instrument to measure disease‐related distress among patients with haemophilia	10
Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with hae	10
Abstract	10
Alternative payment models for durable and potentially curative therapies: The case of gene therapy for haemophilia A	10
Identification of new F8 deep intronic variations in patients with haemophilia A	10
Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC	10
Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study	10
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study	10
Big picture initiatives in bleeding disorders	10
Complications of total knee arthroplasty in patients with haemophilia compared with osteoarthritis and rheumatoid arthritis: A 20‐year single‐surgeon cohort	10
Activity and participation in haemophiliacs: Item response modelling based on international classification of functioning, disability and health	10
Real‐world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years	10
A systematic review of physical activity in people with haemophilia and its relationship with bleeding phenotype and treatment regimen	10
Quantitative measurements of haemophilic joint tissues by point‐of‐care musculoskeletal ultrasound: Associations with clinical and functional joint outcome parameters	10
Diagnosis of haemophilia and other inherited bleeding disorders ‐ Is a new paradigm needed?	10
Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders	9
Patients’ and parents’ satisfaction with, and preference for, haemophilia A treatments: a cross‐sectional, multicentre, observational study	9
Pharmacokinetic‐guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A	9
Critical appraisal of the International Prophylaxis Study Group magnetic resonance image scale for evaluating haemophilic arthropathy	9
A preliminary application of a haemophilia value framework to emerging therapies in haemophilia	9
Management and outcomes of paediatric patients on emicizumab prophylaxis undergoing surgical procedures: Experience from a large haemophilia centre in the UK	9
Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy	9
Effects of a non‐pharmacological approach for chronic pain management in patients with haemophilia: efficacy of cognitive‐behavioural therapy associated with physiotherapy	9
Promoting physical activity for people with haemophilia in the age of new treatments	9
POSTER PRESENTATIONS	9
Real‐world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure:	9
Cost‐utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea	9
Determining meaningful health‐related quality‐of‐life improvement in persons with haemophilia A using the Haemophilia Quality of Life Questionnaire for Adults (Haem‐A‐QoL)	9
Building the blueprint: Formulating a community‐generated national plan for future research in inherited bleeding disorders	9
Low rate of subclinical venous thrombosis in patients with haemophilia undergoing major orthopaedic surgery in the absence of pharmacological thromboprophylaxis	9
Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies	9
Most subjectively affected joints in patients with haemophilia – what has changed after 20 years in Germany?	9
Identified unmet needs and proposed solutions in mild‐to‐moderate haemophilia: A summary of opinions from a roundtable of haemophilia experts	9
Factor product utilization and health outcomes in patients with haemophilia A and B on extended half‐life concentrates: A Canadian observational study of real‐world outcomes	9
Exercise capacity in people with haemophilia: A systematic review	9
Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study	9
Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A	9
Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): Report of two cases and review of literature	9
Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors	8
Challenges of antithrombotic therapy in the management of cardiovascular disease in patients with inherited bleeding disorders: A single‐centre experience	8
The effectiveness of manual therapy in addition to passive stretching exercises in the treatment of patients with haemophilic knee arthropathy: A randomized, single‐blind clinical trial	8

Switching from standard to extended half‐life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics	8
rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: Post hoc analysis of B‐LONG using haemophilia‐specific quality of life questionnaires	8
Effectiveness of emicizumab in preventing life‐threatening bleeding complications in type 3 von Willebrand disease with inhibitors: A paediatric report	8
Clinical and patient reported outcome in total ankle replacement compared to ankle fusion in end‐stage haemophilic arthropathy	8
Acquired bleeding disorders	8
COVID‐19 and telemedicine in haemophilia in a patient with severe haemophilia A and orthopaedic surgery	8
Towards novel treatment options in von Willebrand disease	8
Descriptive analysis of bleeding symptoms in haemophilia carriers enrolled in the ATHNdataset	8
Ultrasound evaluation of joint damage and disease activity in adult patients with severe haemophilia A using the HEAD‐US system	8
Clinical attributes and treatment characteristics are associated with work productivity and activity impairment in people with severe haemophilia A	8
Biomarkers of bone disease in persons with haemophilia	8
Redefining prophylaxis in the modern era	8
Do we need all that emicizumab?	8
Managing invasive procedures in haemophilia patients with limited resources, extended half‐life concentrates or non‐replacement therapies in 2022	8
Haemophilia gene therapy—Update on new country initiatives	8
Therapeutic and technological advancements in haemophilia care: Quantum leaps forward	8
Severe bleeding in a patient with factor XIII deficiency and COVID‐19	8
Real‐world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow‐up in a national adult cohort	8
An evaluation of PROMIS health domains in adults with haemophilia: A cross‐sectional study	8
Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?	7
Addressing patient education priorities in the era of gene therapy for haemophilia: Towards evidence‐informed shared decision‐making	7
Reimbursing the value of gene therapy care in an era of uncertainty	7
Validation of the pictorial blood loss assessment chart using modern sanitary products	7
Efficacy and safety of a recombinant Von Willebrand Factor treatment in patients with inherited Von Willebrand Disease requiring surgical procedures	7
Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma	7
Reappearance of inhibitor in a tolerized patient with severe haemophilia A during FVIII‐free emicizumab therapy	7
Unravelling the knowledge, beliefs, behaviours and concerns of Persons with Haemophilia and their carriers in Senegal	7
Patient satisfaction with US Hemophilia Treatment Center Care, Teams and Services: The First National Survey	7
The role of total ankle replacement in patients with haemophilia and end‐stage ankle arthropathy: A review	7
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Gro	7
Thrombomodulin in patients with mild to moderate bleeding tendency	7
Adherence to prophylaxis and its association with activation of self‐management and treatment satisfaction	7
Successful correction of factor V deficiency of patient‐derived iPSCs by CRISPR/Cas9‐mediated gene editing	7
Clinical characteristics and surgical treatment of haemophilic pseudotumor: A retrospective analysis of thirty‐four patients	7
Recurrence of a high‐titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis	7
Mutation analysis in the F8 gene in 485 families with haemophilia A and prenatal diagnosis in China	7
How to assess, detect, and manage joint involvement in the era of transformational therapies: Role of point‐of‐care ultrasound	7
Pharmacokinetic, efficacy and safety evaluation of B‐domain‐deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A	7
Emicizumab improves thrombus formation of type 2A von willebrand disease under high shear condition	7
PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A	7
Quality of electronic treatment records and adherence to prophylaxis in haemophilia and von Willebrand disease: Systematic assessments from an electronic diary	7
Low dose prophylaxis and antifibrinolytics: Options to consider with proven benefits for persons with haemophilia	7
Depression and anxiety in persons with Von Willebrand disease	7
Laboratory coagulation tests and recombinant porcine factor VIII: A United Kingdom Haemophilia Centre Doctors’ Organisation guideline	7
Health technology assessment for gene therapies in haemophilia	7
Acquired haemophilia A after alemtuzumab therapy	7
A comparison of MyPKFiT and WAPPS‐Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa	7
Single centre, real‐world experience of perioperative rFIXFc use in adult patients with haemophilia B undergoing major and minor surgery	7
Case report of a fatal rectal haemorrhage in a person with severe haemophilia A receiving emicizumab and high‐dose bypassing agents in the HAVEN 1 study	6
Patient‐reported outcomes in autosomal inherited bleeding disorders: A systematic literature review	6
Early wound complications after orthopaedic surgery for haemophilia: What can we do more	6
Optimal trough levels in haemophilia B: Raising expectations	6
Inhibition of Fenton reaction is a novel mechanism to explain the therapeutic effect of intra‐articular injection of PRP in patients with chronic haemophilic synovitis	6
Acupuncture as a therapeutic resource for treatment of chronic pain in people with haemophilia	6
Thromboelastometry detects enhancement of coagulation in blood by emicizumab via intrinsic pathway	6
Global epidemiology of factor XI deficiency: A targeted review of the literature and foundation reports	6
Approximation of emicizumab plasma levels in emergency situations. A practical approach	6
Acquired bleeding disorders	6
Limited sampling strategies for accurate determination of extended half‐life factor VIII pharmacokinetics in severe haemophilia A patients	6
Bleeding with iron deposition and vascular remodelling in subchondral cysts: A newly discovered feature unique to haemophilic arthropathy	6
Assessment of the clinical perception, quality of life and satisfaction of patients with severe congenital haemophilia A without inhibitor after 1 year of emicizumab therapy	6
Changes in pain profile of patients with haemophilia during 1‐year follow‐up	6
Patient and caregiver preferences for haemophilia A treatments: A discrete choice experiment	6
Sports participation of patients with haemophilia in the COVID‐19 era: The Dutch experience	6
An immediate hypersensitivity reaction induced by PEGylated recombinant factor VIII	6
Pain, depression and anxiety in people with haemophilia from three Nordic countries: Cross‐sectional survey data from the MIND study	6
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors	6
Inhibitors—Recent insights	6
Effectiveness of physical exercise on postural balance in patients with haemophilia: A systematic review	6
Bone health in haemophilia carriers and persons with von Willebrand disease: A large database analysis	6
Aerobic exercise in patients with haemophilia: A systematic review on safety, feasibility and health effects	6
Individualised prophylaxis based on personalised target trough FVIII level optimised clinical outcomes in paediatric patients with severe haemophilia A	6
Gene therapy – are we ready now?	6
Real‐world evidence on health resource use among patients with haemophilia and inhibitor exhibiting severe bleeding episodes	6
Bleeding complications during pregnancy and delivery in haemophilia carriers and their neonates in Western France: An observational study	6
Substitution therapy	6
Safety of FEIBA and emicizumab (SAFE): Dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab	6
Pain memories: A new concept to consider in the management of chronic pain in people with haemophilia	6
A phase IV, multicentre, open‐label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures	6
Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027	6
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors	6
Drug‐associated acquired hemophilia A: an analysis based on 185 cases from the WHO pharmacovigilance database	6
Severe haemophilia A children on low‐dose tertiary prophylaxis showed less joint deterioration and better maintenance of functional independence than children on on‐demand treatment: A 6‐year follow‐u	6
The societal burden of haemophilia A. I – A snapshot of haemophilia A in Australia and beyond	6
Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B	6
The effects of manual therapy on musculoskeletal system, functional level, joint health and kinesiophobia in young adults with severe haemophilia: A randomized pilot study	6
Impact of COVID‐19 pandemic on mental health of patients with inherited bleeding disorders in Germany	6
Ultrasound and patient self‐imaging in hemophilia	6
Treatment outcomes in persons with severe haemophilia B in the Nordic region: The B‐NORD study	6
Natural history study of factor IX deficiency with focus on treatment and complications (B‐Natural)	6
Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centres	6
Isokinetic knee strength deficit in patients with moderate haemophilia	5
Ultrasound and magnetic resonance imaging for the detection of blood: An ex‐vivo study	5
Haemophilia management and treatment: An Italian survey on patients’, caregivers’ and clinicians’ point of view	5
Postpartum haemorrhage in women with mild factor XI deficiency	5